Topics

Companies Related to "Tmunity Francisco Announce Exclusive License Research Collaboration Advance" [Most Relevant Company Matches] [Advanced Search Results] RSS

06:46 EST 12th November 2019 | BioPortfolio

Here are the most relevant search results for "Tmunity Francisco Announce Exclusive License Research Collaboration Advance" found in our extensive corporate database of over 50,000 company records.

Showing "Tmunity Francisco Announce Exclusive License Research Collaboration Advance" Companies 1–25 of 8,200+

Extremely Relevant

Tmunity Therapeutics, Inc. and FierceBiotech

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) and the groundbreaking scientific, clinical and manufacturing ex...


Relevant

Tmunity Therapeutics, Inc.

Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota with the groundbreaking scientific, clini...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...


Takeda San Francisco Inc.

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and development of antibodies, enhancement of antibody activity and antibody-manufacturing in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco i...

Merck and Cardiome Pharma Corp.

In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and Dohme Corp. (formerly known as Merck & Co., Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with AF, and...

Cell>Point

Cell>Point is a clinical-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in Ho...

Acumen Pharmaceuticals, Inc.

The Merck Collaboration helps Acumen both scientifically and financially advance our own drug discovery programs. Acumen has the ability to use all know how and intellectual property generated in the Collaboration for our own Small Molecule programs. As Merck’s programs advance toward the clinic, Acumen is eligible for certain milestone payments which help fund these discovery and development ...

Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Take...

ADVENTRX Pharmaceuticals, Inc.

ADVENTRX Pharmaceuticals, Inc. is the result of a merger, effective October 10, 2000, between BioQuest, Inc., a public company, and Biokeys, Inc., a privately held entity. The two companies adjusted outstanding shares, options, and warrants on a 50/50 basis.The Company entered into an Option and License Agreement with the University of Southern California (USC) in January 1998 for exclusive rights...

Abeome Corporation

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance.

San Francisco Health Plan

San Francisco Health Plan is a licensed community health plan that provides affordable health coverage to low and moderate-income San Franciscans. San Francisco Health Plan was designed for and by the residents it serves - many of whom would not be able to otherwise obtain health care for themselves or their families. San Francisco Health Plan's mission is to provide superior, affordable health ca...

Engitix

Engitix was established in 2016 to develop and commercialise research at the UCL Institute for Liver and Digestive Health, Division of Medicine. The Company was founded by Professor Massimo Pinzani and Dr Giuseppe Mazza and has an exclusive license from UCLB to enabling ECM patents and other intellectual property. Engitix is based at the Royal Free Hospital ...

North American Neuromodulation Society (NANS)

The North American Neuromodulation Society (NANS) is the premier organization representing neuromodulation in the United States and is the largest member of the International Neuromodulation Society. NANS promotes multidisciplinary collaboration among clinicians, scientists, engineers, and others to advance neuromodulation therapies through education, rese...

CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark for its ECM Technology as an implant for pericardial closure and for use in cardiac tissue repair.

Advance - Global Australian Professionals

Advance - Global Australian Professionals is for all Australians working overseas. From accountants to zoologists, becoming a member is your way of staying connected, keeping informed and investing in your future. Joining is free! Advance is a community of Australian professionals overseas headquartered in New York City, with established chapters in Boston, Chicago, Los Angeles, San Francisco, Wa...

Bio-Bridge Science

Bio-Bridge Science, Inc., a development stage biotechnology company, engages in the commercial development of vaccines for the prevention and treatment of human infectious diseases. The company is currently developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). It develops HIV vaccines for both preventive and therapeutic purposes. ...

iZumi Bio, Inc.

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. Th...

BioCrossroads

BioCrossroads (www.biocrossroads.com) is Indiana's initiative to grow, advance and invest in the life sciences, a publicprivate collaboration that supports the region's existing research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises (Indiana Health Information Exchang...

Cadent Therapeutics

Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advan...

AxioMed Spine Corporation

AxioMed Spine Corporation was formed to develop products for restoring native function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Led by an experienced and proven management team, AxioMed has developed a next-generation technology platform for artificial disc implants that is characterized by: · T...

Synergenz BioScience Ltd

Synergenz BioScience Ltd is a research leader in genomic tests for respiratory medicine. It was formed in 2004 to further advance discoveries first made by Dr. Robert Young at The University of Auckland in New Zealand, where studies continue in collaboration with leading researchers and the company's commercial partners around the world.

iBridge Network

The iBridge(SM) Network is an innovation catalyst with a vibrant, online community enabling universities, companies and entrepreneurs to connect, collaborate and license tomorrow's research, products and services. Many of the nation's leading research institutions utilize the iBridge(SM) Network regularly to promote, share and advance their innovations and identify appropriate partners. The iBridg...

Mediomics, LLC

Dr. Yie-Hwa Chang founded the Company in August 2001. The Company is commercializing core technologies for which it has secured an exclusive license from Saint Louis University, including the following: (i) Bridge-It®, a DNA-binding protein-based bioassay platform, (ii) a related variant – the molecular PINCER®-based homogeneous biosensor and bi...

MCNC

MCNC is an independent, non-profit organization that employs advanced networking technologies and systems to continuously improve learning and collaboration throughout North Carolina's K-20 education community. MCNC provides advanced communications technologies and support services that enable access to 21st century learning applications and offers the opportunity to improve teaching, learning, r...

Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and...


More From BioPortfolio on "Tmunity Francisco Announce Exclusive License Research Collaboration Advance"

Quick Search

Corporate Database Quicklinks